Literature DB >> 2477071

CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: its relationship to severity of dementia and monoamine metabolites.

N Pomara1, R R Singh, D Deptula, P A LeWitt, G Bissette, M Stanley, C B Nemeroff.   

Abstract

The concentration of corticotropin-releasing factor-like immunoreactivity (CRF-LI) in the cerebrospinal fluid (CSF) of 15 probable Alzheimer's disease (AD) patients with mild to moderate dementia and 10 neurologically normal age-matched controls was examined. There were no significant alterations in the mean CSF CRF-LI concentration in AD compared to controls. However, in the AD group, CSF CRF-LI correlated significantly with the global neuropsychological impairment ratings, suggesting that greater cognitive impairment was associated with lower CSF CRF-LI concentrations. There was a significant reduction in the CSF concentration of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) in the AD patients, and there was a positive correlation between the concentration of CRF-LI and 5-HIAA in CSF. This latter finding suggests that serotoninergic neuronal systems may interact with CRF-containing neurons.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477071     DOI: 10.1016/0006-3223(89)90071-1

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  18 in total

1.  Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease.

Authors:  Hongxin Dong; Keely M Murphy; Liping Meng; Janitza Montalvo-Ortiz; Ziling Zeng; Benedict J Kolber; Shanshan Zhang; Louis J Muglia; John G Csernansky
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

Review 3.  Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets.

Authors:  Francis J Herman; Sherry Simkovic; Giulio M Pasinetti
Journal:  Br J Pharmacol       Date:  2019-03-21       Impact factor: 8.739

Review 4.  Sculpting the hippocampus from within: stress, spines, and CRH.

Authors:  Pamela M Maras; Tallie Z Baram
Journal:  Trends Neurosci       Date:  2012-03-02       Impact factor: 13.837

5.  Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-β and behavior in Tg2576 mice.

Authors:  Hongxin Dong; Shirlene Wang; Ziling Zeng; Fei Li; Janitza Montalvo-Ortiz; Christopher Tucker; Shahzad Akhtar; Jingshan Shi; Herbert Y Meltzer; Kenner C Rice; John G Csernansky
Journal:  Psychopharmacology (Berl)       Date:  2014-05-27       Impact factor: 4.530

Review 6.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

7.  Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed non-matching to position tests.

Authors:  John B Hogan; Donald B Hodges; Snjezana Lelas; Paul J Gilligan; John F McElroy; Mark D Lindner
Journal:  Psychopharmacology (Berl)       Date:  2004-10-14       Impact factor: 4.530

Review 8.  Class II G protein-coupled receptors and their ligands in neuronal function and protection.

Authors:  Bronwen Martin; Rakel Lopez de Maturana; Randall Brenneman; Tom Walent; Mark P Mattson; Stuart Maudsley
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 9.  Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: the role of the locus coeruleus.

Authors:  H Lehnert; C Schulz; K Dieterich
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

Review 10.  Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology.

Authors:  Makoto Ishii; Costantino Iadecola
Journal:  Cell Metab       Date:  2015-09-10       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.